Virtu KCG Holdings LLC bought a new stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 114,507 shares of the biotechnology company’s stock, valued at approximately $124,000. Virtu KCG Holdings LLC owned approximately 0.48% of Viking Therapeutics at the end of the most recent reporting period.

Separately, Renaissance Technologies LLC increased its holdings in shares of Viking Therapeutics by 62.9% during the 1st quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock valued at $388,000 after purchasing an additional 102,600 shares in the last quarter. Institutional investors own 5.54% of the company’s stock.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02).

VKTX has been the subject of several recent research reports. Maxim Group reaffirmed a “buy” rating and set a $5.00 target price on shares of Viking Therapeutics in a report on Wednesday, October 4th. ValuEngine lowered shares of Viking Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price (up from $5.00) on shares of Viking Therapeutics in a report on Monday, July 17th.

ILLEGAL ACTIVITY WARNING: “Virtu KCG Holdings LLC Takes $124,000 Position in Viking Therapeutics, Inc. (VKTX)” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.